Vertex Pharmaceuticals, Inc. (VRTX) Tops Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $468.42 +0.35%
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +8.4%
Financial Fact:
Loss before provision for income taxes: -39.03M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q4 EPS of $0.86, $0.16 better than the analyst estimate of $0.70. Revenue for the quarter came in at $563.3 million versus the consensus estimate of $518.36 million.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
